Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- No Licensing Deal Clinched for First AMED-Backed Drug Seed
March 14, 2016
- MHLW’s Info Gathering System for Pediatric Drugs Goes Live
March 14, 2016
- Japan to Lead Initiatives to Disseminate Regulatory Submission, Review Rules in APEC
March 14, 2016
- MHLW Wants to Continue Price Maintenance Scheme for On-Patent Drugs: Shiozaki
March 11, 2016
- Shiozaki Seeks Understanding for “Huge-Seller” Drug Re-Pricing
March 11, 2016
- Drug Makers Should Have Freewheeling Discussions towards 2018 Reform, MHLW Wants to Pick Their Brains: Official
March 10, 2016
- “Huge Seller” Re-Pricing Dominates Discussions at LDP Study Group
March 10, 2016
- 76 Products Join Japanese Pharmacopoeia: MHLW
March 10, 2016
- Difficult to Enact Clinical Research Bill in Current Diet Session: LDP Health Panel Chief
March 9, 2016
- PMDA Aims to Complete Reviews for 70% of Priority Products within 9 Months in FY2016
March 9, 2016
- MHLW Sorts Out Schemes for Humanitarian Trials, Patient-Initiated Mixed Care
March 8, 2016
- 77.8% of Generics Converge into Single Price Brand in FY2016 Revision: MHLW
March 7, 2016
- Drug Damage Watchdog Says NOAC Makers Paid Big for People Involved in AF Guidelines
March 7, 2016
- Editor’s Pick: Five Healthcare Policy News Headlines for February
March 4, 2016
- MHLW Panel Sets Official Price of Raw Plasma for Coagulation Factor Products at 11,100 Yen per Liter
March 4, 2016
- 439 APIs/1,057 Long-Listed Products Subject to Z2 Price Cut Rule in FY2016 Revisions
March 4, 2016
- AMED Selects 8 Projects for Pre-Orphan Designation System, 3 from Nobelpharma
March 4, 2016
- 416 APIs Eligible for Price Maintenance Scheme in FY2016 Revision; Astellas Only Japanese in Top 10 Premium Winner List
March 4, 2016
- Sovaldi, Harvoni Face 31.7% Price Cut under “Huge Seller” Re-Pricing: MHLW
March 4, 2016
- MHLW to Revise Label Format, Possibly Scrap “Relative Contraindications” and “Careful Administration” Sections
March 3, 2016
ページ
Japanese Prime Minister Sanae Takaichi has pledged to respond to the US most-favored-nation (MFN) drug pricing policy to safeguard timely…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…